Protein tyrosine kinases as therapeutic targets in cancer chemotherapy and recent advances in the development of new inhibitors

References

• GLENNEY JR: Tyrosine-phosphorylated proteins - me-diators of signal tran.sduction from the tyrosine ki-nases. Biochim. Biophys. Acta (1992) 1134:113–127.
   PubMed Web of Science ®Google Scholar
• CADENA DL, GILL GN: Receptor tyrosine kinases. FASEB J. (1992) 6:2332–2337.
   PubMed Web of Science ®Google Scholar
• CHANG CJ, GEAHTFN RL: Protein-tyrosine kinase inhibi-tion - mechanism-based discovery of antitumor agents. J. Nat. Prod. (1992) 55:1529–1560.
   PubMed Web of Science ®Google Scholar
• BURICE TR: Protein-tyrosine kinase inhibitors. Drugs Fut.(1992) 17:119–131.
   Google Scholar
• SCHLESSINGER J, ULLRICH A: Growth factor signaling byreceptor tyrosine kinases. Neuron (1992) 9:383–391.
   PubMed Web of Science ®Google Scholar
• PANAYOTOU G, WATERFIELD MD: The assembly of sig-naling complexes by receptor tyrosine kinases. hoes-says(1993) 15:171–177.
   Google Scholar
• CHIAO PJ, BISCHOFF FZ, STRONG LC, TAINSICY MA: Thecurrent status of oncogenes and cancer: Experimental approaches for analyzing oncogenetic events in human cancer Cancer and Metast. Rev. (1990) 9:63–80.
   Google Scholar
• HUNTER T: Cooperation between oncogenes. Cell (1991)64:249–270.
   PubMed Web of Science ®Google Scholar
• AARONSON SA: Growth factors and cancer. Science(1991) 254: 1146–1153.
   PubMed Web of Science ®Google Scholar
• CANTLEY LC, AUGER KR, CARPENTER C, DUCKWORTH B, GRAZIANI A, KAPELLER R, SOLTOFF S: Oncogenes and signal transduction. Cell (1991) 64:281–302.
   PubMed Web of Science ®Google Scholar
• KAPLAN DR, PERKINS A, MORRISON DK: Signal transduc-tion by receptor tyrosine kinases. In: Oncogenes and Tumor Suppressor Genes in Human Malignancies. Benz CC, Liu ET (Eds), Kluwer Academic Publishers, Boston 1993 pp. 265–279.
   Google Scholar
• ULLRICH A, SCHLESSINGER J: Signal transduction by receptors with tyrosine kinase activity. Cell (1990) 61:203–212.
   PubMed Web of Science ®Google Scholar
• BRUNTON VG, WORKMAN P: Cell-signaling targets for antitumour drug development. Cancer Chem other. Phar-macol. (1993) 32:1–19.
   PubMed Web of Science ®Google Scholar
• Excellent review on the concept of targeting cell signaling compo-nents for cancer therapy.
   Google Scholar
• WORKMAN P: Signal transduction inhibitors as novel anticancer drugs: Where are we? Ann. Oncol. (1992) 3:527–531.
   Google Scholar
• ELDER JT, FISHER Gj, LINDQUIST PB, BENNET GL, PIT-TELKOW MR, COFFEY RJ, ELLINGSWORTH L, DENRYNCK R, VOORHEES II: Overexpression of transforming growth factor a in psoriatic epidermis. Science (1989) 243:811–814.
   PubMed Web of Science ®Google Scholar
• VASSAR R, FUCHS E: Transgenic mice provide new Insights into the role of TGFa during epidermal devel-opment and differentiation. Gene Dev. (1991) 5:714–727.
   PubMed Web of Science ®Google Scholar
• ROSS R: Platelet derived growth factor. lancet (1989)1:1179–1182.
   PubMed Web of Science ®Google Scholar
• HADAR DP, POMERANTZ KB: Signal transduction in atherosclerosis: integration of cytokines and the ei-cosanoid network. EASES J. (1992) 6:2933–2941.
   Google Scholar
• KLAGSBRUN M, EDELMAN ER: Biological and biochemi-cal properties of fibroblast growth factors. Implications for the pathogenesis of atherosclerosis. Arteriosclerosis (1989) 9:269–278.
   Google Scholar
• LIBBY P, SCHWARTZ D, BROGI E, TANAKA H, CLINTONSK: A cascade model for restenosis - a special case of atherosclerosis progression. Circulation (December 1992) 86:47–52.
   PubMed Web of Science ®Google Scholar
• SCHWARTZ RS, HOLMES DR, TOPOL EJ: The restenosisparadigm revisited: An alternative proposal for celhilar mechanisms. J. Am. Coll. Cardiol. (1992) 20:1284–1293.
   PubMed Web of Science ®Google Scholar
• NOMURA Y, KITAMURA Y, TOHDA M, TOKUMITSU Y: Drugs acting on the intracellular signaling system. Medicinal Research Reviews (1993) 13:1–60.
   PubMed Web of Science ®Google Scholar
• LEVITZKI A: Tyrphostins: tyrosine kinase blockers as novel antiproliferative agents and dissectors of signal transduction. FASEB (1992) 6:3275–3282.
   PubMed Web of Science ®Google Scholar
• KHAZAIE K, SCHIRRMACHER V, LICHTNER RB: EGF recep-tor in neoplasia and metastasis. CancerMetast. Rev. (1993) 12:255–274.
   PubMed Web of Science ®Google Scholar
• HAYMAN MJ, ENRIETTO PJ: Cell transformation by theepidermal growth factor receptor and v-erbB. Cancer Cells (1991) 3:302–307.
   PubMed Web of Science ®Google Scholar
• RIEDEL H, MASSOGLIA J, SCHLESSINGER J, ULLRICH A: Ligand activation of overexpressed epidermal growth factor receptors transforms NIII-3T3 mouse fibroblasts. Proc. Natl. Acad. (1988) 85:1477–1481.
   PubMed Web of Science ®Google Scholar
• VELU TJ, BEGUINOT L, VASS WC, WILLINGHAM MC, MER-LINO GT, PASTAN I, LOWY DR: Epidermal growth factor-dependent transformation by a human EGF receptor proto-oncogene. Science (1987) 238:1408–1410.
   PubMed Web of Science ®Google Scholar
• STERN DF, HARE DL, CECCHINI MA, WEINBERG RA: Con-struction of a novel oncogene based on synthetic se-quences encoding epidermal growth factor. Science (1987) 235:321–324.
   PubMed Web of Science ®Google Scholar
• SANDGREN EP, LUE11EKE NC, PALMITER RD, BRINSTEREL, LEE DC: Overexpression of TGF-alpha in transgenic mice: induction of epithelial hyperplasia, pancreatic metaplasia, and cardnoma of the breast Cell (1990) 61:1121–1135.
   Google Scholar
• JHAPPAN C, STAHLE C, HARIUNS RN, FAUST° N, SMITH GH, MERLIN() GT: TGF alpha overexpression in trans-genic mice induces liver neoplasia and abnormal devel-opment of the mammary gland and pancreas. Cell(1990) 61:1137–1146.
   PubMed Web of Science ®Google Scholar
• LEE DC, LUETTEKE NC, PETCH LA: Transforming growth factor-alpha and its role in neoplastic progression. In: Oncogenes and Tumor Suppressor Genes in Human Malig-nancies. Benz CC, Liu ET (Eds), Kluwer Academic Publishers, Boston 1993 pp. 233–254.
   Google Scholar
• I.F.F DC, LUETTEKE NC, QIU TH, CHEN XR, BERKOWITZ EA: Transforming growth factor-alpha - its expression, regulation, and role in transformation. In: Growth Fac-tors in Perinatal Development. Tsang RC, Lemons JA, Balls-treri (Eds), Raven Press, New York 1993 pp.21–38.
   Google Scholar
• References 31 and 32 provide the latest data on TGF-a transgenic mice.
   Google Scholar
• WATKINS LF, LEVINE AE: Differential role of transform-ing growth factor-alpha in two human colon-carcinoma cell lines. Int. J. Cancer (1991) 47:455–460.
   PubMed Web of Science ®Google Scholar
• MORISHIGE K, KURACHI H, AMEMIYA K, ADACHI H, INOUE M, MIYAKE A, TANIZAWA O, SAKOYAMA Y: In-volvement of transforming growth factor-alpha/epi-dermal growth factor receptor autocrine growth mechanism in an ovarian cancer cell line in vitro. Cancer Res. (1991) 51:5951–5955.
   PubMed Web of Science ®Google Scholar
• MODfTAHEDI H, ECCLES S, BOX G, STYLES J, DEAN C:Immunotherapy of human tumour xenografts overex-pressing the EGF receptor with rat antibodies that block growth factor-receptor interaction. Br./ Cancer (1993) 67:254–261.
   PubMed Web of Science ®Google Scholar
• KURACHI H, MORISHIGE K-I, AMEMIYA K, ADACHI H, HIROTA K, MIYAKE A, TANIZAWA O: Importance of transforming growth factor alpha/epidermal growth factor receptor autocrine growth mechanism in an ovarian cancer cell line in vivo. Cancer Res'. (1991) 51: 5956–5959.
   PubMed Web of Science ®Google Scholar
• MASUI H, MOROYAMA T, MENDELSOHN J: Mechanism ofantitumor activity in mice for anti-epidermal growth factor receptor monoclonal antibodies with different isotypes. Cancer Res. (1986) 46:5592–5598.
   PubMed Web of Science ®Google Scholar
• RODECK U, HERLYN M, HERLYN D, MOLTHOFF C, ATKIN-SON B, VARELLO M, STEPLEWSKI Z, KOPROWSKI H: Tumor growth modulation by a monoclonal antibody to the epidermal growth factor receptor: Immunologi-cally mediated and effector cell-independent effects. Cancer Res. (1987) 47:3692–3696.
   PubMed Web of Science ®Google Scholar
• GUAN E, ZHOU T, WANG J, HUANG P, TANG W, ZHAO M,CHEN Y, SUN Y: Growth inhibition of human naso-pharyngeal carcinoma in athymic mice by anti-epider-mal growth factor receptor monoclonal antibodies. Internat. J. Cell Clan. (1989) 7:242–256.
   PubMedGoogle Scholar
• MASUI H, KAWAMOTO T, SATO JD, WOLF B, SATO G,MENDELSOHN j: Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monockmal antibodies. Cancer Res. (1984) 44:1002–1007.
   PubMed Web of Science ®Google Scholar
• PRIGENT SA, LEMOINE NR: The type 1 (EGFR-related) family of growth factor receptors and their ligands. Frog. Growth Factor Res. (1992) 4:1–14.
   PubMedGoogle Scholar
• GULLICK WJ: Prevalence of aberrant expression of the epidermal growth factor receptor in human cancers. Br. Med. Bulletin (1991) 47:87–98.
   PubMed Web of Science ®Google Scholar
• LIBERMAN TA, RAZON N, BARTAL AD, YARDEN Y, SO-MESSINGER J, SOREQ H: Expression of epidermal growth factor receptors in human brain tumors. Cancer Res. (1984) 44:753–7611
   PubMed Web of Science ®Google Scholar
• SMITH K, FENNELLY JA, NEAL DE, HALL RR, HARRIS AL:Characterization and quantitation of the epidermal growth factor receptor in invasive and superficial blad-der tumors. Cancer Res. (1989) 49:5810–5815.
   PubMed Web of Science ®Google Scholar
• HAUGEN DR, AKSLEN LA, VARHAUG JE, LI1LFHAUG JR: Demonstration of a TGF-alpha-EGF-receptor autocrine loop and c-myc protein over-expression in papillary thyroid carcinomas. Int. J. Cancer (1993) 55:37–43.
   PubMed Web of Science ®Google Scholar
• KANAMORI A, ABE Y, YAJIMA Y, MANABE Y, ITO K: Epidermal growth factor receptors in plamsa mem-branes of normal and diseased human thyroid glands. J. Clin. Endocrinol. Metab. (1989) 68:899–903.
   PubMed Web of Science ®Google Scholar
• LIU C, TSAO MS: In vitro and in vivo expressions of transforming growth factor-alpha and tyrosine kinase receptors in human non-small-cell lung carcinomas. Amer. J. Pathol. (1993) 142:1155–1162.
   PubMed Web of Science ®Google Scholar
• DITTADI R, GION M, PAGAN V, BRAZZALE A, MASCHIOOD, BARGOSSI A, BUSETTO A, BRUSCAGNIN G: Epider-mal growth factor receptor in lung :malignancies. Com-parison between cancer and normal tissue. Br.J. Cancer (1991) 64:741–744.
   PubMedGoogle Scholar
• LUNDY J, SCHUSS A, STANICK D, MCCORMACK ES, KRA-MER S, SORVILLO JM: Expression of neu protein, epider-mal growth factor receptor, and transforming growth factor-alpha in breast cancer - correlation with clinico-pathologic parameters. Amer. J. Pathol. (1991) 138:1527–1534.
   PubMed Web of Science ®Google Scholar
• LEWIS S, LOCKER A, TODD 311, BELL JA, NICHOLSON R,ELSTON CW, BLAMEY RW, ELLIS 10: Expression of epi-dermal growth factor receptor in breast carcinoma. J. Clin. Pathol. (1990) 43:385–389.
   PubMed Web of Science ®Google Scholar
• TOT M, OSAKI A, YAMADA H, TOGE T: Epidermal growthfactor receptor expression as a prognostic indicator in breast cancer. Eur. J. Cancer (1991) 27:977–980.
   PubMed Web of Science ®Google Scholar
• LEE EY, WANG TC, CLOUSE RE, DESCHRYVERICECSKEMETIK: Gastric carcinoma, epidermal growth factor, and epidermal growth factor receptor. Gastroenterology (1991) 100:289.
   PubMed Web of Science ®Google Scholar
• LEMOINE NR, JAIN S, SILVESTRE F, LOPES C, HUGHES CM,MCLELLAND E, GULLICK WJ, FILIPE MI: Amplification and overexpression of the EGF receptor and c-erbB-2 proto-oncogenes in human stomach cancer. Brit. J. Cancer (1991) 64:79–83.
   PubMed Web of Science ®Google Scholar
• STEELE R: Epidermal growth factor receptor expressionIn colorectal cancer. British I Sing. (1990) 77:1352–1354.
   PubMed Web of Science ®Google Scholar
• LIBERMANN TA, NUSBAUM HE, RAZON N, KRIS R, LAX I,SOREQ H, WHITTLE N, WATERFIELD MD, ULLRICH A, SCHLESSINGER J: Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumors of glial origin. Nature (1985) 313:144–147.
   PubMed Web of Science ®Google Scholar
• YAMAMOTO T, KAMATA N, KAWANO H, SHIMIZU S, KUROKI T, TOYOSHIMA K, RIICIMARU K, NOMURA N, ISHIZAKI R, PASTAN I: High incidence of amplification of the epidermal growth factor receptor gene in human squamous carcinoma cell lines. Cancer Res. (1986) 46:414–416.
   PubMed Web of Science ®Google Scholar
• MUKAIDA H, TOT M, HIRAI T, YAMASHITA Y, TOGE T:Clinical significance of the expression of epidermal growth factor and its receptor in esophageal cancer. Cancer (1991) 68:142–148.
   PubMed Web of Science ®Google Scholar
• KOPROWSKI H, HERLYN M, BALABAN G, PARM1TER A,ROSS A, NOWELL P: Expression of the receptor for epidermal growth factor correlates with increased dos-age of chromosome 7 in malignat melanoma. Somatic Cell. Mol. Genet. Cancer Res. (1985) 11:297–305.
   PubMedGoogle Scholar
• HUMPHREY PA, WONG Aj, VOGELSTEIN B, FRIEDMAN HS,WERNER MH, BIGNER DD BIGNER SH: Amplification and expression of the epidermal growth factor receptor gene in human g,lioma xenografts. Cancer Res. (1988) 48:2231–2238.
   PubMed Web of Science ®Google Scholar
• YAMAZAKI H, FUKUI Y, UEYAMA Y, TAMAOKI N, KAWAMOTO T, TANIGUCHI S, SHIBUYA M: Amplification of the structurally and functionally altered epidermal growth factor receptor gene (c- erbB) in human brain tumors. Mol. Cell. Biol. (1988) 8:1816–1820.
   PubMed Web of Science ®Google Scholar
• ARTEAGA CL, HANAUSICE AR, CLARK GM, OSBORNE CK,HAZARIKA P, PARDUE RL, TIO F, VON HOFF DD: un-munoreactive alpha-transforming growth factor activ-ity in effusions from can patients as a marker of tumor burden and patient prognosis. Cancer Res. (1988) 48:5023–5028.
   PubMed Web of Science ®Google Scholar
• YASUI W, HATA J, YOKOZAKI H, NAICATANI H, OCHIAI A,ITO H, TAHARA E: Interaction between epidermal growth factor and its receptor in progression of human gastric carcinoma. Int. J. Cancer (1988) 41:211–217.
   PubMed Web of Science ®Google Scholar
• BARTON CM, HALL PA, HUGHES CM, GULLICK WJ, LEMOINE NR: Transforming growth factor alpha and epidermal growth factor in human pancreatic cancer. J. Path. (1991) 163:111–116.
   PubMed Web of Science ®Google Scholar
• MACIAS A, AZAVEDO E, HAGERSTROM T, KLINTENBERG C, PEREZ R, SKOOG L: Prognostic significance of the receptor for epidermal growth factor in human mam-mary carcinomas. Anticancer Res. (1987) 7:459–464.
   PubMed Web of Science ®Google Scholar
• GRIMAUX M, ROMAIN S, REMVIKOS Y, MARTIN PM, MAG-DELENAT H: Prognostic value of epidermal growth factor receptor in node-positive breast cancer. Breast Cancer Res. Treat. (1989) 14:77–90.
   PubMed Web of Science ®Google Scholar
• TOT M, NAKAMURA T, MUKAIDA H, WADA T, OSAKI A, YAMADA H, TOGE T, NIIMOTO M, HATTORI T: Relation-ship between epidermal growth factor receptor status and various prognostic factors in human breast cancer. Cancer (1990) 65:1980–1984.
   PubMed Web of Science ®Google Scholar
• NICHOLSON S, RICHARD J, SAINSBURY C, HALCROW P, KELLY P, ANGUS B, WRIGHT C, HENRY J, FARNDON JR, HARRIS AL: Epidermal growth factor receptor (EGFr); results of a 6 year follow-up study in operable breast cancer with emphasis on the node negative subgroup. Br. J. Cancer (1991) 63:146–150.
   PubMed Web of Science ®Google Scholar
• HENDLER FJ, SHUM-SIU A, OECHSLIM, NANU L, RICHARDS CS, OZANNE BW: Increased EGF-R1 binding predicts a poor survival in squamous tumors. Cancer Cells (1989) 7:347–351.
   Google Scholar
• NEAL DE, MARSH C, BENNETT MK, ABEL PD, HALL RR, SAINSBURY JRC, HARTS AL: Epidermal growth factor receptors in human bladder cancer: comparisons of Invasive and superficial tumors. lancet (1985) i:366–368.
   Google Scholar
• MAXWELL SA, SACKS PG, GU1TERMAN JU, GALLICK GE: Epidermal growth factor receptor protein-tyrosine ki-nase activity in human cell lines established from squamous carcinomas of the head and neck. Cancer Res. (1989) 49:1130–1137.
   PubMed Web of Science ®Google Scholar
• MODYTAHEDI H, DEAN C: The receptor for EGF and its ligands - expression, prognostic value and target for therapy in cancer. Int. J. Oncol. (1994) 2:277-296. Most up to date review on the involvement of the EGF receptor in human cancer.
   Google Scholar
• YARDEN Y, PELES E: Biochemical analysis of the ligand for the neu oncogenic receptor. Biochemistry (1991) 30:3543–3550.
   PubMed Web of Science ®Google Scholar
• DOUGALL WC, QIAN X, GREENE MI: Interaction of the nett/13185 and EGF receptor tyrosine kinases: Implica-tions for cellular transformation and tumor therapy. J. Cell. Biokhetn. (1993) 53:61–73.
   Google Scholar
• LUPU R, COLOMER R, KANNAN B, LIPPMAN ME: Charac-terization of a growth factor that binds exclusively to the erbB-2 receptor and induces cellular responses. Proc. Natl. Acad. Sci. USA (1992) 89:2287–2291.
   PubMed Web of Science ®Google Scholar
• WEN DZ, PELES E, CUPPLES R, SUGGS SV, BACUS SS, LUO Y, TRAEL G, HU S, SILBIGER SM, BENLEVY R, KOSKI RA, LU HS, YARDEN Y: Neu differentiation factor - A transmem-brane glycoprotein containing an EGF domain and an immunoglobulin homology unit. Cell (1992) 69:559–572.
   PubMed Web of Science ®Google Scholar
• HOLMES WE, SLIWKOWSKI MX, AKITA RW, HENZEL WJ, LEE J, PARK JW, YANSURA D, ABADI N, RAAB H, LEWIS GD, SHEPARD HM, KUANG WJ, WOOD WI, GOEDDEL DV, VANDLEN RL: Identification of heregulin, a specific activator of p185(erbb2). Science (1992) 256: 1205–1210.
   PubMed Web of Science ®Google Scholar
• PELES E, YARDEN Y. Neu and its ligands: From an oncogene to neural factors. BioEssays (1993) 15:815–824.
   PubMed Web of Science ®Google Scholar
• Excellent article reviewing recent infornation of ligands for erbB-2.
   Google Scholar
• LUPU R, LIPPMAN ME. The role of erbB2-signal transduc-tion pathways in human breast cancer. Breast Cancer Res. Treat. (1993) 27:83–93
   PubMed Web of Science ®Google Scholar
• YARDEN Y: Agonistic antibodies stimulate the kinaseencoded by the neu proto-oncogene in living cells but the oncogenic mutant is constitutively active. Proc. Natl. Acad. Sci. USA (1990) 87:2569–2573.
   PubMed Web of Science ®Google Scholar
• BARGMANN CI, WEINBERG RA: Oncogenic activation ofthe neu- encoded receptor protein by point mutation and deletion. EMBO (1988) 7:2043–2052.
   PubMed Web of Science ®Google Scholar
• STERNBERG MJE: Neu receptor dimerization. Nature (1989) 339:587.
   PubMed Web of Science ®Google Scholar
• SUDA Y, AIZAWA S, FLTRUTA Y, YAGI T, IKAWA Y, SAITOH K, YAMADA Y, TOYOSHIMA K, AND YAMAMOTO T: Induction of a variety of tumors by c-erbB2 and clonal nature of lymphomas even with the mutated gene (Va1659---61u659). EMBO J. (1990) 9:203–212.
   Google Scholar
• SAYA H, ARA S, LEE PSY, RO J, HUNG MC: Direct sequenc-ing analysis of transmembrane region of human neu gene by polymerase chain reaction. Mol. Carinogen. (1990) 3:198–201.
   PubMed Web of Science ®Google Scholar
• LEMOINE NR, STADDON S, DICKSON C, BARNES DM, GULLICK WJ: Absence of activating transmembrane mu-tations in the c-erbB-2 proto-oncogene in human breast cancer. Oncogene (1990) 5:237–239.
   PubMed Web of Science ®Google Scholar
• HUDZIAK EM, SCHLESSINGER J, ULLRICH A: Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells. Proc. Natl. Acad. Sci. USA (1987) 84:7159–7163.
   PubMed Web of Science ®Google Scholar
• DI FIORE PP, PIERCE JH, KRAUS MH, SEGATTO O, KING CR, AARONSON SA: erbB-2 Is a potent oncogene when overexpressed in NIH/3T3 cells. Science (1987) 237:178–182.
   PubMed Web of Science ®Google Scholar
• References 85 and 86 provide the first demonstration that normal c-erbB-2 can transform cells.
   Google Scholar
• MULLER WJ, SINN E, PA1 ihNGALE PK, WALLACE R, LEDER P: Single-step induction of mammary adenocarcinoma In transgenic mice bearing the activated c-neu onco-gene. Cell (1988) 54:105–115.
   PubMed Web of Science ®Google Scholar
• GUY CT, 'WEBSTER MA, SCHALLER M, PARSONS TJ, CAR-DIFF RD, MULLER WJ: Expression of the neu proto-on-cogene in the mammary epithelium of transgenic mice Induces metastatic disease. Proc. Natl. Acad. Sci USA (1992) 89:10578–10582.
   PubMed Web of Science ®Google Scholar
• BOUCHARD L, LAMARRE L, TREMBLAY PJ, JOLICOEUR P:Stochastic appearance of mammary tumors in trans-genic mice carrying the 1101TV/c-neu oncogene. Cell (1989) 57:931–936.
   PubMed Web of Science ®Google Scholar
• WANG BC, KENNAN WS, YASUKAWA-BARNES J, LIND-STROM MJ, GOULD MN: Frequent induction of mammary carcinomas following neu oncogene transfer into in situ mammary epithelial cells of susceptible and resis-tant rat strains. Cancer Research (October 15, 1991) 51: 5649–5654.
   Google Scholar
• SHEPARD HM, LEWIS GD, SARUP JC, FENDLY BM, MANEVAL D, MORDENTI J, FIGARI I, KOTTS CE, PALLAD-INO MA, ULLRICH A, SLAMON D: Monoclonal antibody therapy of human can - taking the ber2 proto-onco-gene to the clinic. J. Clin. Immunol. (1991) 11:117–127.
   PubMed Web of Science ®Google Scholar
• TAGUABUE E, CENTIS F, CAMPIGLIO M, MASTROIANNI A,MARTIGNONE S, PELLEGRINI R, CASALINI P, LANZI C, MENARD S, COLNAGHI MI: Selection of monoclonal antibodies which induce internalization and phospho-rylation of p185ber2 and growth inhibition of cells with ber2/neu gene amplification. Internat. J. Cancer (1991) 47:933–937.
   PubMed Web of Science ®Google Scholar
• KERN JA, TORNEY L, WEINER D, GAZDAR A, SHEPARD HM, FENDLY B: Inhibition of human lung cancer cell line growth by an anti- p185(ber2) antibody. Amer. J. Reap. Cell Mol. Biol. (1993) 9:448–454.
   PubMed Web of Science ®Google Scholar
• DREBIN JA, LINK VC, WEINBERG RA, GREENE MI: Inhibi-tion of tumor growth by a monoclonal antibody reac-tive with an oncogene-encoded tumor antigen. Proc. Natl. Acad. Sci. USA (1986) 83:9129–9133.
   PubMed Web of Science ®Google Scholar
• DREBIN JA, LINK VC, GREENE ME: Monoclonal antibodies specific for the nets oncogene product directly mediate antitumor effects in vivo. Oncogene (1988) 2:387–394.
   PubMed Web of Science ®Google Scholar
• DREBIN JA, LINK VC, GREEN MI: Monoclonal antibodies reactive with distinct domains of the neu oncogene-en-coded p185 molecule exert synergistic antitumor ef-fects. Oncogene (1988) 2:273–277.
   PubMed Web of Science ®Google Scholar
• Demonstration that erbB-2 is a viable target in cancer chemotherapy.
   Google Scholar
• KASPRZYK PG, SONG SU, DI FIORE PP, KING CR: Therapy of an animal model of human gastric cancer using a combination of anti-erbB-2 monoclonal antibodies. Cancer Res. (1992) 52:2771–2776.
   PubMed Web of Science ®Google Scholar
• HARWERTH IM, WELS W, SCHLEGEL J, MULLER M, HYNESNE: Monoclonal antibodies directed to the erbb-2 recep-tor inhibit in vivo tumour cell growth. Brit. J. Cancer (1993) 68:1140–1145.
   PubMed Web of Science ®Google Scholar
• STANCOVSKI I, HURWITZ E, LEITNER O, ULLRICH A, YARDEN Y, SELA M: Mechanistic aspects of the opposing effects of monoclonal antibodies to the ERBB2 receptor on tumor growth. Proc. Natl. Acad Sci. USA (1991) 88:8691–8695.
   PubMed Web of Science ®Google Scholar
• PAM SM: Clinical significance of erbB2 (ber-2/neu) protein. Cancer Invest. (1992) 10:575–579.
   PubMed Web of Science ®Google Scholar
• OIICICANEN S, HELIN H, ISOLA J, JOENSUU H: Prognostic significance of HER-2 oncoprotein expression in breast cancer - a 30-year follow-up. J. Clin. Oncol. (1992) 10: 1044–1048.
   PubMed Web of Science ®Google Scholar
• GASPARINI G, GULLICK NX7J, BEVILACQUA P, SAINSBURY RC, MELT S, BORACCHI P, TESTOLIN A, LA MALFA G, POZZA F: Human breast cancer: prognostic significance of the c-erbB-2 oncoprotein compared with epidermal growth factor receptor, DNA ploidty, and conventional pathologic features. J. ain. Oncol. (1992) 10:686–695.
   PubMed Web of Science ®Google Scholar
• IOCCA DR, FUJIMURA FK, TANDON AK, CLARK GM, MARK C, LEECHEN GJ, POUNDS GW, VENDELY P, OWENS MA, PANDIAN MR, MCGUIRE WE: Correlation of her-2/neu amplification with expression and with other prognos-tic factors in 1103 breast cancers. INCI (1992) 84:1279–1282.
   PubMed Web of Science ®Google Scholar
• ELLEDGE RM, MCGUIRE WE, OSBORNE CK: Prognostic factors in breast cancer. Sem. Oncol. (1992) 19:244–253.
   PubMed Web of Science ®Google Scholar
• TYSON FL, BOYER CM, KAUFMAN R, OBRIANT K, CRAM G, CREWS JR, SOPER JT, DALY L, FOWLER WC, HASKILL JS, BAST RC: Expression and amplification of the her-2/neu (c-erbB-2)proto-oncogene in epithelial ovarian tumors and cell lines. Amer. J. Obstet. Gynecol. (1991) 165:640–646.
   PubMed Web of Science ®Google Scholar
• RUBIN SC, FINSTAD CL, WONG GY, ALMADRONES L, PLANTE M, LLOYD KO: Prognostic significance of her-2/near expression in advanced epithelial ovarian cancer - a multivariate analysis. Amer. J. Obstet. Gynecol. (1993) 168:162–169.
   PubMed Web of Science ®Google Scholar
• MIZUTANI T, ONDA M, TOKUNAGA A, YAMANAKA N, SUGISAKI Y: Relationship of c-erbB-2 protein expres-sion and gene amplification to invasion and metastasis In human gastric cancer. Cancer (1993) 72:2083–2088.
   PubMed Web of Science ®Google Scholar
• UCHINO S, TSUDA H, MARUYAMA K, KINOSHITA T, SASAKO M, SAITO T, KOBAYASHI M, HIROHASHI S: Over-expression of c-erbB-2 protein in gastric cancer - its correlation with long-term survival of patients. Cancer (1993) 72:3179–3184.
   PubMed Web of Science ®Google Scholar
• ZHAU HE, ZHANG X, VON ESCHENGACH AC, SCORSONE K, BABAIAN RJ, RO JY, HUNG MC: Amplification and expression of the c-erb B-2/neu proto-oncogene in human bladder cancer. Mol. Carcin. (1990) 3:254–257.
   PubMed Web of Science ®Google Scholar
• WOOD DP, WARTINGER DD, REUTER V, CORDONCARDO C, FAIR WR, CHAGANTI RSK: DNA, RNA and knnnunohis-tochemical characterization of the HER2/neu oncogene in transitional cell carcinoma of the bladder. J. lira (1991) 146:1398–1401.
   Google Scholar
• TATEISHI M, ISHIDA T, MITSUDOMI T, KANEKO S, SUGI-MACHI K: Prognostic value of c-erbB-2 protein expres-sion in human lung adenocarcinoma and squamous cell carcinoma. Eur. J. Cancer (1991) 27:1372–1375.
   PubMed Web of Science ®Google Scholar
• KERN JA, SCHWARTZ DA, NORDBERG JE, WEINER DB, GREENE MI, TORNEY L, ROBINSON RA: p185neu expres-sion in human lung adenocarcinomas predicts short-ened survival. Cancer Res. (1990) 50:5184–5191.
   PubMed Web of Science ®Google Scholar
• SHI DR, HE GP, CAO SL, PAN WS, ZHANG HZ, YU DH, HUNG MC: Overexpression of the c-erb B-2/ness encoded p185 protein in primary lung can. Mol. Carcinogen. (1992) 5:213–218.
   PubMed Web of Science ®Google Scholar
• VANETTEN RA: Malignant transformation by abl and bcr/abL In: Oncogenes and Tumor Suppressor Genes in Human Malignancies. Benz CC, Liu ET (Eds), Kluwer Aca-demic Publishers, Boston 1993 pp. 167–192.
   Google Scholar
• CLARK SS, CRIST WM, 'COTTE ON: Molecular pathogenesis of Ph-positive leukemias. Annu. Rev. Med. (1989) 40:113–122.
   PubMed Web of Science ®Google Scholar
• LUGO TG, PENDERGAST AM, MULLER AJ, WITTE ON: Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science(1990) 247:1079–1082.
   PubMed Web of Science ®Google Scholar
• KELLIHER M, KNOTT A, MCLAUGHLIN J, WITTE ON, ROSENBERG N: Differences in oncogenic potency but not target cell specificity distinguish the two forms of the bcr/abl oncogene. Mol. Cell. Biol. (1991) 11:4710–4716.
   PubMed Web of Science ®Google Scholar
• MCWH1RTER JR, WANG JYJ: Activation of tyrosine kinase and microthament-binding functions of c-abl by bcr sequences in bcr/abi fusion proteins. Mol. Cell. Biol. (1991) 11:1553–1565.
   PubMed Web of Science ®Google Scholar
• MULLER AJ, YOUNG JC, PENDERGAST AM, PONDEL M, LANDAU NR, LITTMAN DR, WITTE ON: BCR first exon sequences specifically activate the BCR/ABL tyrosine kinase oncogene of Philadelphia chromosome-positive human leukemias. Mol. Cell. Biol. (1991) 11: 1785–1792.
   PubMed Web of Science ®Google Scholar
• PENDERGAST AM, MULLER AJ, HAVLIK MIL MARU Y, Wri IL ON: BCR sequences essential for transformation by the bcr-abl oncogene bind to the abl-SH2 regulatory domain in a non-phosphotyrosine- dependent man-ner. Cell (1991) 66:161–171.
   PubMed Web of Science ®Google Scholar
• MARU Y, WITTE ON: The BCR gene encodes a novel serine/ threonine kinase activity within a single exon. Cell (1991) 67:459–468.
   PubMed Web of Science ®Google Scholar
• PENDERGAST AM, MULLER AJ, HAVLIK MH, CLARK R, MCCORMICK F, WITTE ON: Evidence for regulation of the human abl tyrosine kinase by a cellular inhibitor. Proc. Nat. Acad. Sci. USA (July 1991) 88:5927–5931.
   PubMed Web of Science ®Google Scholar
• MARU Y, WITTE ON: How does the chimeric BCR-ABL oncogene function in human chronic myelogenous leukemia. In: Application of Basic Science to Hematopoiesis and Treatment of Disease? Thomas ED (Ed) Raven Press, New York 1993 pps 123–143.
   Google Scholar
• Excellent review on the contribution of the BCR-ABL oncogene to chronic myelogenous leukemia.
   Google Scholar
• HARIHARAN IK, HARRIS AW, CRAWFORD M, ABUD H, WEBB E, CORY S, ADAMS J: bcr-v-abl oncogene induces lymphomas in transgenic mice. Mol. Cell. Biol. (1989) 9:2798–2805.
   PubMed Web of Science ®Google Scholar
• HEISTERKAMP N, JENSTER G, TEN HOEVE J, ZOVICH D, PA11 ENGALE PK, GROFFEN J: Acute leukaemia in bcr/abl transgenic mice. Nature (1990) 344:251–253.
   PubMed Web of Science ®Google Scholar
• GISHIZKY ML, JOHNSON-WHITE J, WITTE ON: Efficient transplantation of BCR-Al3L-induced chronic myelo-genous leukemia- like syndrome in mice. Proc. Natl. Acad. Sci. USA (1993) 90:3755–3759.
   PubMed Web of Science ®Google Scholar
• ELEFANTY AG, HARIHARAN LK, CORY S: Bcr-abl, the hallmark of chronic myeloid leukaemia in man, in-duced multiple haemopoietic neoplasms in mice. EMBO (1990) 9:1069–1078.
   PubMed Web of Science ®Google Scholar
• SCOTT ML, VAN E 11 EN RA, DALEY GQ, BALTIMORE D: V-abl causes hematopoietic disease distinct from that caused by bcr-abL Proc. Natl. Acad. Sci. USA (1991) 88:6506–6510.
   PubMed Web of Science ®Google Scholar
• SZCZYLIK C, SKORSKI T, NICOLAIDES NC, MANZELLA L, 8* MALAGUARNERA L, VENTTURELLI D, GEWIRTZ AM, CALABRE1f A B: Selective inhibition of leukemia cellproliferation by BCR-ABL antisense oligodeoxynu-cleotides. Science (1991) 253:562–565.
   PubMed Web of Science ®Google Scholar
• Supports the concept that inactivating the BCR-ABL oncogene will selectively kill leukaemia cells harbouring this gene.
   Google Scholar
• JAYE M, SCHLESSINGER J, DIONNE CA: Fibroblast growth factor receptor tyrosine kinases - molecular analysis and signal transduction. Biochim. Biophys. Acta (1992) 1135:185–199.
   PubMed Web of Science ®Google Scholar
• BREM H, KIAGSBRUN M: The role of fibroblast growth factors and related oncogenes in tumor growth. In: Oncogenes and Tumor Suppressor Genes in Human Malig-nancies. Benz CC, Liu ET (Eds), Kluwer Academic Publishers, Boston 1993 pps. 211–231.
   Google Scholar
• Review of FGF and its possible involvement in cancer.
   Google Scholar
• HUGHES SE, HALL PA: The fibroblast growth factor and receptor multigene fan] Ries. J. Patbol. (1993) 170:219–221.
   Google Scholar
• MOORE R, CASEY G, BROOKES S, DIXON M, PETERS G, DICKSON C: Sequence topography and protein coding potential of mouse int-2: a putative oncogene activated by mouse mammary tumour virus. EMBOJ. (1986) 5:919–924.
   PubMed Web of Science ®Google Scholar
• SAKAMOTO H, MORI M, TAIRS M, YOSHIDA T, MATSUK-AWA S, SHIMIZU K, SEKIGUCHI M, TERADA M, SUGIMURA T: Transforming gene from human stomach cancers and a noncancerous portion of stomach mucosa. Proc. Natl. Acad. Sci. USA (1986) 83:3997–4001.
   PubMed Web of Science ®Google Scholar
• DELLI-BOVI P, BASILICO C: Isolation of a rearranged human transforming gene following transfection of Kaposi sarcoma DNA. Proc. Natl. Acad. Sci. USA (1987) 84:5660–5664.
   PubMed Web of Science ®Google Scholar
• ZHAN X, CULPEPPER A, REDDY M, LOVF.I.FSS J, GOLDFARB M: Human oncogenes detected by a defined medium culture assay. Oncogenes (1987) 1:369–376.
   PubMed Web of Science ®Google Scholar
• DICKSON C, PLIERS G: Potential oncogene product related to growth factors. Nature (1987) 326:833.
   PubMed Web of Science ®Google Scholar
• BLAM SB, MITCHEL R, TISCHER E, RUBIN JS, SILVA M, SILVERS, F1DDES JC, ABRAHAM JA, AARONSON SA: Addi-tion of growth hormone secretion signal to basic fi-broblast growth factor results in cell transformation and secretion of aberrant forms of the protein. Onco-gene (1988) 3:129–136.
   Google Scholar
• JAYE M, LYALL RM, MUDD R, SCHLESSINGER J, SARVER N: Expression of acidic fibroblast growth factor cDNA confers growth advantage and tumorigenesis to Swiss 3T3 cells. EMBO J. (1988) 7:963–969.
   PubMed Web of Science ®Google Scholar
• NEUFELD G, MITCHELL R, PONTE P, GOSPODAROWICZ D: Expression of human basic fibroblast growth factor cDNA in baby hamster kidney-derived cells results in autonomous cell growth. J. Cell Biol.(1988) 106:1385–1394.
   PubMed Web of Science ®Google Scholar
• ROGEL JS, WEINBERG RA, FANNING P, KLAGSBRUN M: Basic fibroblast growth factor fused to a signal peptide transforms cells. Nature (1988) 331:173–175.
   PubMed Web of Science ®Google Scholar
• TAYLOR WR, GREENBERG AH, TURLEY EA, WRIGHT JA: Cell motility, invasion, and malignancy induced by overexpression of k-FGF or bFGF. Fxper. Cell Res. (1993) 204: 295–301.
   PubMed Web of Science ®Google Scholar
• SASADA R, KLTROKAWA T, "WANE M, IGARASHI K: Trans-formation of mouse BALB/c 3T3 cells with human basic fibroblast growth factor cDNA. Mol. Cell. Biol. (1988) 8:588–594.
   PubMed Web of Science ®Google Scholar
• HALABAN R: Growth factors and tyrosine protein ki-nases in normal and maligant melanocytes. Cancer Metast. Rev. (1991) 10:129–140.
   PubMed Web of Science ®Google Scholar
• RODECK U, BECKER D, HERLYN M: Basic fibroblast growth factor in human melanoma. Cancer Cells (1991) 3:308–311.
   PubMed Web of Science ®Google Scholar
• GROSS JL, HERBLIN WE, DUSAK BA, CZERNIAK P, DIA-MOND MD, SUN T, EIDSVOOG K, DEXTER DL, YAYON A: Effects of modulation of basic fibroblast growth factor on tumor growth in vivo. JNCI (1993) 85:121–131.
   PubMed Web of Science ®Google Scholar
• FOLKMAN T, KAGSBRUN M: Angiogenic factors. Science (1987) 235:442–447.
   PubMed Web of Science ®Google Scholar
• THOMPSON TA, ANDERSON IdD, DIPIETRO TM, ZWIEBEL TA, ZAMEllk, M, ANDERSON WF, MACIAG T: Site-directed neovessel formation in vivo. Science (1988) 241:1349–1352.
   PubMed Web of Science ®Google Scholar
• HORI A, SASADA R, MATSUTANI E, NAITO K, SAKUR Y, FUJITA T, KOZAI Y: Suppression of solid tumor growth by immunoneutralizing monoclonal antibody against human basic fibroblast growth factor. Cancer Res. (1991) 51:6180–6184.
   PubMed Web of Science ®Google Scholar
• ZHOU DJ, CASEY G, CLINE MJ: Amplification of human int-2 in breast cancers and squamous carcinomas. On-cogene (1988) 2:279–282.
   Google Scholar
• LIDEREAU R, CALLAHAN R, DICKSON C, PETERS G, ESCOT C, ALI IU: Amplification of the int-2 gene in primary human breast tumors. Oncogene Res. (1988) 2:285–291.
   PubMedGoogle Scholar
• THEILET C, LE ROY X, DE LAPEYRIERE O, GROSGEORGES J, ADNANE J, RAYNAUD SD, SIMONY-LAFONTALNE J, GOLDFARB M, ESCOT C, BIRNBAUM D, GAUDRAY P: Amplification of FGF-rrelated genes in human tumors: possible involvement of USE in breast carcinomas. Oncogene (1989) 4:915–922.
   PubMed Web of Science ®Google Scholar
• LISCIA DS, MERLO GR, GARRETT C, FRENCH D, MARIANI-COSTANTINI R, CALLAHAN R: Expression of int-2 mRNA In human tumors amplified at the itn-2 locus. Oncogene (1989) 4:1219–1224.
   PubMed Web of Science ®Google Scholar
• WALKER RE, VARLEY JNI: The molecular pathology of human breast cancer. Cancer Surv. (1993) 16:31–57.
   PubMedGoogle Scholar
• HENRY JA, HENNESSY C, LEVETT DL, LENNARD TWj, WESTLEY BR, MAY FEB: Int-2 amplification in breast cancer: association with decreased survival and rela-tionship to amplification of c-erbB-2 and c-myc. Int. J. Cancer (1993) 53: 774–780.
   PubMed Web of Science ®Google Scholar
• ADNANE J, GAUDRAY P, DIONNE CA, CRUMLEY G, JAYE M, SCHLESSINGER J, JEANTEUR P, BIRNBAUM D, THEIIIFT C: BEK and FLG, two receptors to members of the FGF family, are amplified in subsets of human breast can-cers. Oncogene (1991) 6:659–663.
   PubMed Web of Science ®Google Scholar
• DOOLITTLE RE, HUNKAPILLER MW, HOOD LE, DEVARE SG, ROBBINS KC, AARONSON SA, ANTONIADES HN: Sim-ian sarcoma virus onc gene, v-sts, is derived from the gene (or genes) encoding a platelet-derived growth factor. Science (1983) 221:275–277.
   PubMed Web of Science ®Google Scholar
• WATERFIELD MD, SCREACE GT, WHITTLE N, STROOBANT P, JOHNSSON A, WASTESON A, WESTERMARK B, HELDIN C, HUANG JS, DEUEL TF: Platelet-derived growth factor is structurally related to the putative transforming protein p28sis of simian sarcoma virus. Nature (1983) 304:35–39.
   PubMed Web of Science ®Google Scholar
• KEATING MT, WILLIAMS LT: Autocrine stimulation of intracellolgr PDGF receptors in v-sis-transformed cells. Science (1988) 239:914–916.
   PubMed Web of Science ®Google Scholar
• BEJCEK BE, LI DY, DEUEL TF: Transformation by v-sis occurs by an internal autoactivation mechanism. Sci-ence (1989) 245:1496–1499.
   PubMed Web of Science ®Google Scholar
• MALIK R, GOPE M, WOMER RB, NAGASHUNMUGAM T, MARGOLIN JP, BASU A, SCHER CD: Structure and expres-sion of the beta-platelet- derived growth factor receptor gene in human tumor cell lines. Cancer Research (1991) 51:5626–5631.
   PubMed Web of Science ®Google Scholar
• MACARTHUR LH, CLARICE ME, WESTIN EH: Malignant transformation of N111 3t3 fibroblasts by human c-sis is dependent upon the level of oncogene expression. Mol. Carcinogen. (1992) 5:311–319.
   PubMed Web of Science ®Google Scholar
• LAROCHEI IF WJ, FLEMING TP, AARONSON SA: PDGF in cell transformation. In: Biology ofPlatelet - Derived Growth Factor. Cytokines, Westerrnark B, Sorg C (Eds) Basel, Karger 1993, 5:129–145.
   Google Scholar
• Review on the involvement of PDGF in cancer.
   Google Scholar
• JOHNSON A, BETSHOLTZ C, HELDIN C, WESTERMARK B: Antibodies against platelet-derived growth factor in-hibit acute transformation by simian sarcoma virus. Nature (1985) 317:438–440.
   PubMed Web of Science ®Google Scholar
• FLEMING TP, MATSUI T, AARONSON S: Platelet-derived growth factor (PDGF) receptor activation in cell trans-formation and human malignancy. Ex p. Gerontol. (1992) 27:523–32.
   PubMed Web of Science ®Google Scholar
• SHAMAH SM, STILES CD, GUHA A: Dominant-negative mutants of platelet-derived growth factor revert the transformed phenotype of human astrocytoma cells. Mol. Cell Biol. (1993) 13:7203–7212.
   PubMed Web of Science ®Google Scholar
• BECKMANN MP, BETSHOLTZ C, HELDIN C-H, WESTER-MARK B, MARCO ED, DI FIORE PP, ROBBINS KC, AARON-SON SA: Comparison of biological properties and transforming potential of human PDGF-A and PDGF-B chains. Science (1988) 241:1346–1349.
   PubMed Web of Science ®Google Scholar
• WESTERMARK B, SLEGBAHN A, HELDIN CH, CLAESSON-WLSH L: B- type receptor for platelet-derived growth factor mediates a chemotactic response by means of ligand-induced activation of the receptor protein-tyro-sine kinase. Proc. Natl. Acad. Sci. USA (1990) 87:128–132.
   PubMed Web of Science ®Google Scholar
• ESCOBEDO J, WILLIAMS LT: A PDGF receptor domain essential for mitogenesis but not for many other re-sponses to PDGF. Nature (1988) 87:85–87.
   Google Scholar
• WESTERMARK B: PDGF and its receptors in human tumor cells In: Biology of Platelet - Derived Growth Factor. Cytokines. Westermark B, Sorg C (Eds) Basel, Karger 1993 5:146–162.
   Google Scholar
• SILVER BJ: Platelet-derived growth factor in human malignancy. Biofactors (1992) 3:217–227.
   PubMed Web of Science ®Google Scholar
• FLEMING 'FP, MATSUI T, HEIDARAN MA, MOLLOY CJ, ARTRIP J, AARONSON SA: Demonstration of an activated platelet-derived growth factor autocrine pathway and its role in human tumor cell proliferation in vitro. Oncogene (1992) 7:1355–1359.
   Google Scholar
• LEITZEL K, BRYCE W, TOMITA J, MANDERINO G, TRIBBY I, THOMASON A, BILLINGSLEY M, PODCZASKI E, HARVEY H, BARTHOLOMEW M, UPTON A: Elevated plasma plate-let-derived growth-factor-b-chain levels in cancer pa-tients. Cancer Res. (1991) 51: 4149–4154.
   PubMed Web of Science ®Google Scholar
• ARIAD S, SEYNIOUR L, BEZWODA WR: Platelet-derived growth factor (PDGF) in plasma of breast can pa-tients: correlation with stage and rate of progression. Breast Cancer Research and Treatment (1991) 20:11–17.
   PubMed Web of Science ®Google Scholar
• SEYMOUR L, DAJEE D, BEZWODA WR: Tissue platelet derived-growth factor (PDGF) predicts for shortened survival and treatment failure in advanced breast can-cer. Breast Cancer Res. Treat. (1993) 26:247–252.
   PubMed Web of Science ®Google Scholar
• BOLEN JB: Nonreceptor tyrosine protein kinases. Onco-gene (1993) 8:2025–2031.
   Google Scholar
• BRICKELL PM: The p60c-src family of protein-tyrosine kinases: structure, regulation, and function. Cri t. Rev. Oncogen. (1992) 3:401–446.
   PubMedGoogle Scholar
• JOVE R, HANAFUSA H: Cell transformation by the viral arc oncogene. Ann. Rev. Biol. (1987) 3:31–56.
   PubMedGoogle Scholar
• LIEBL EC, MARTIN GS: Intracellular targeting of pp6Osrc expression - loc•livation of v-src to adhesion plaques Is sufficient to transform chicken embryo fibroblasts. Oncogene (1992) 7:2417–2428.
   PubMed Web of Science ®Google Scholar
• COBB BS, SCHALLER MD, LEU TH, PARSONS JT: Stable association of pp60(src) and pp59(j5iis) with the focal adhesion-associated protein tyrosine kinase, pp125(fak). Mol. Cell. Biol. (1994) 14:147–155.
   PubMed Web of Science ®Google Scholar
• SHALLOWAY D, SHENOY S: Oncoprotein kinases in mitosis. Adv. Cancer Res. (1991) 57:185–225.
   PubMed Web of Science ®Google Scholar
• WYKE AW, CUSHLEY W, WYKE JA: Mitogenesis by v-src: A need for active oncoprotein both in leaving GO and In completing 61 phases of the cell cycle. Cell Growth Differ. (1993) 4:671–678.
   PubMedGoogle Scholar
• TSUKITA S, OISHI K, AKIYAMA T, YAMANASHI Y, YAMAMOTO T, TSUKITA S: Specific proto-oncogenic tyrosine kinases ofsrc family are enriched in cell-to-cell adherens junctions where the level of tyrosine phos-phorylation is elevated. J. Cell Biol. (1991) 113:867–879.
   PubMed Web of Science ®Google Scholar
• ICELLIE S, HORVATH AR, ELMORE MA: Cytoskeletal targets for oncogenic tyrosine kinases. J Cell Sci. (1991) 99:207–211
   PubMed Web of Science ®Google Scholar
• CLARK EA, BRUGGE JS: Redistribution of activated pp60c-src to integrin-dependent cytoskeletal com-plexes in thrombin- stimulated platelets. Mol. Cell. Biol. (1993) 13:1863–1871.
   PubMed Web of Science ®Google Scholar
• HUNTER T: A tail of two src's: mutat& mutandis. Cell (1987) 49:1–4.
   PubMed Web of Science ®Google Scholar
• ROSEN N, BOLEN JB, SCHWARTZ AM, COHEN P, DESEAU V, ISRAEL MA: Analysis of pp60c-src protein kinase activity in human tumor cell lines and tissues. J. Biol. Chem. (1986) 261:13754–13759.
   PubMed Web of Science ®Google Scholar
• BOLEN JB: Activation of pp60c-str protein kinase activ-ity in human colon carcinoma. Proc. Natl. Acad. Sci. USA (1987) 84:2251–2255.
   PubMed Web of Science ®Google Scholar
• BOLEN JB, VEILLETTE A, SCHWARTZ AM, DESEAU V, ROSEN N: Analysis of pp60c-src in human colon carci-noma and normal human colon mucosal cells. Onco-gene Res. (1987) 1:149–168.
   PubMedGoogle Scholar
• BARNEKOW A, PAUL E, SCHARTL M: Expression of the c-src protoonocogene in human skin tumors. Cancer Res. (1987) 47:235–240.
   PubMed Web of Science ®Google Scholar
• CARTWRIGHT C, KAMPS M, MEISLER A, PIPAS J, ECKHART W: pp60c- src activation in human colon cancer. J. Clin. Invest. (1989) 83: 2025–2032.
   PubMed Web of Science ®Google Scholar
• JACOBS C, RUBSAMEN H: Expression of pp60c-src pro-tein kin•s*- in adult and fetal human tissue: high activi-ties in some sarcomas and mammary carcinomas. Cancer Res. (1983) 43:1696–1702.
   PubMed Web of Science ®Google Scholar
• FANNING P, BULOVAS K, SAINI KS, L1BERTINO JA, JOYCE AD, SUMMERHAYES IC: Elevated expression of pp60c-src In low grade human bladder carcinomas. Cancer Res. (1992) 52:1457–1462.
   PubMed Web of Science ®Google Scholar
• TALAMONTI MS, ROH MS, CURLEY SA, GALLICK GE: In- crease in activity and level of pp60c-src in progressive stages of human colorectal cancer. J. Clin. Invest. (1993) 91:53–60.
   PubMed Web of Science ®Google Scholar
• High correlation between the activity of pp60c-sre and progression of colon cancer.
   Google Scholar
• HENNIPMAN A, VAN OIRSCHOT BA, SMITS J, RIJKSEN G, STAAL GEJ: Tyrosine kin•se activity in breast cancer, benign breast disease, and normal breast tissue. Cancer Res. (1989) 49:516–521.
   PubMed Web of Science ®Google Scholar
• OTTENHOFFKALFF AE, RIJKSEN G, VANBEURDEN EACM, HENNIPMAN A, MICHELS AA, STAAL GEJ: Charac-terization of protein tyrosine kinases from human breast cancer - involvement of the c-src oncogene product. Cancer Res. (1992) 52:4773–4778.
   PubMed Web of Science ®Google Scholar
• MUTHUSWAMY SK, SIEGEL PM, DANKORT DL, WEBSTER MA, MULLER WJ: Mammary tumors expressing the nen proto-oncogene possess elevated c-src tyrosine ldnase activity. Mol. Cell. Biol. (1994) 14:735–743.
   PubMed Web of Science ®Google Scholar
• LUTTRELL DK, LEE A, LANSING TJ, CROSBY RM, JUNG kD, WILLARD D, LUTHER M, RODRIGLTEZ M, BERMAN J, GIL-MER TM: Involvement of pp6Osrc with two major sig-naling pathways in human breast cancer. Proc. Natl. Acad. Sci. USA (1994) 91:83–87.
   PubMed Web of Science ®Google Scholar
• GUY CT, MUTHUSWAMY SK, CARDIFF RD, SORIANO P, MULLER WJ: Activation of the c-src tyrosine kinase isrequired for the induction of mammary tumors in transgenic mice Genes & Develop. (1994) 8:23–32.
   Google Scholar
• PP60c-stc kinase activity is necessary for the development of mam-mary tumors in mice transfected with the polyoma middle T onco-gene.
   Google Scholar
• GAZIT A, YAISH P, GILON C, avrrzm A: Tyrphostins. 1. Synthesis and biological activity of protein tyrosine kinase inhibitors. J. Med. Chem. (1989) 32:2344–2352.
   Google Scholar
• GAZIT A, OSHEROV N, POSNER I, YAISH P, PORADOSU E, GILON C, LEVITZKI A: Tyrphostins. 2. Heterocyclic and a-substituted benzylidenemalononitrile tyrphostins as potent inhibitors of EGF receptor and erbB2/neu tyro-sine kinases. J. Med. Chem. (1991) 34:1896–1907.
   Google Scholar
• GAZIT A, OSHEROV N, POSNER I, BARSINA1 A, GILON C, LEVITZKI A: Tyrphostins. 3. Structure-activity relation-ship studies of alpha-substituted benzylidene-malononitrile 5-S-aryltyrphostins. J. Med. Chem. (1993) 36:3556–3564.
   Google Scholar
• LEVITZKI A, GILON C: Tyrphostins as molecular tools and potential antiproliferative drugs. Trends Pharmacol. Sci. (1991) 12:171–174.
   PubMed Web of Science ®Google Scholar
• DVIR A, MILNER Y, CHOMSKY O, GILON C, GAZIT A, LEVITZKI A: The inhibition of EGF-dependent prolifera-tion of keratinocytes by tyrphostin tyrosine kinase blockers. J. Cell Biol. (1991) 113:857–865.
   PubMed Web of Science ®Google Scholar
• BILDER GE, KRAWLEC JA, MCVETY K, GAZIT A, GILON C, LYALL R, ZILBERSTEIN A, LEVITZKI A, PERRONE MH, SCHREIBER AB: Tyrphostins inhibit PDGF-induced DNA synthesis and associated early events in smooth muscle cells. Amer. j Physiol. (1991) 260:C721–C730.
   PubMed Web of Science ®Google Scholar
• BRYCICAERT MC, ELDOR A, FONTENAY M, GAZIT A, OSHEROV N, GILON C, LEVITZKI A, TOBELEM G: Inhibi-tion of platelet-derived growth factor-induced mito-genesis and tyrosine kinase activity in cultured bone marrow fibroblasts by tyrphostins. Exp. Cell Res. (1992) 199:255–261.
   PubMed Web of Science ®Google Scholar
• RENDU F, ELDOR A, GRELAC F, BACHELOT C, GAZIT A, GILON C, LEVYLOLEDANO S, LEVITZKI A: Inhibition of platelet activation by tyrosine kinase inhibitors. Bio-chem. Pharmacol. (1992) 44:881–888.
   PubMed Web of Science ®Google Scholar
• OSHEROV N, GAZIT A, GILON C, LEVITZKI A: Selective inhibition of the epidermal growth factor and ber2/neu receptors by tyrphostins. J. Biol. Chem. (1993) 268:11134–11142.
   PubMed Web of Science ®Google Scholar
• Demonstration of inhibitory discrimination between EGF receptor and erbB-2.
   Google Scholar
• REDDY KB, MANGOLD GL, TANDON AK, YONEDA T, MUNDY GR, ZILBERSTEIN A, OSBORNE CK: Inhibition of breast cancer cell growth in vitro by a tyrosine kinase Inhibitor. Cancer Res. (1992) 52:3636–3641.
   PubMed Web of Science ®Google Scholar
• GILLESPIE J, DYE JF, SCHACHTER M, GUILLOU PJ: Inhibi-tion of pancreatic cancer cell growth in vitro by the tyrphostin group of tyrosine kinase inhibitors. Brit. J. Cancer (1993) 68:1122–1126.
   PubMed Web of Science ®Google Scholar
• ANAFI M, GAZIT A, GILON C, BENNERIAH Y, LEVITZKI A: Tyrphostin-induced differentiation of mouse erythroleultemia cells. FEBS Lett. (1993) 330:260–264.
   PubMed Web of Science ®Google Scholar
• ANAFI M, GAZIT A, ZEHAVI A, BENNERIAH Y, LEVITZKI A: Tyrphostin-induced inhibition of p210(bcr-ab0 tyro-sine kinase activity induces K562 to differentiate. Blood (1993) 82:3524–3529.
   PubMed Web of Science ®Google Scholar
• YONEDA, T, LYALL RN, ALSINA MM, PERSONS PE, SPADA AP, LEVITZKI A, ZILBERSTEIN A, MUNDY G. R.: The anitproliferative effects of tyrosine kinase inhibitors tyrphostins on a human squamous cell carcinoma in vitro and in nude mice. Cancer Res. (1991) 51:4430–4435.
   Google Scholar
• One of the few reports demonstrating in vivo antitumor activity with a tyrosine kinase inhibitor.
   Google Scholar
• SHIRAISHI T, OWADA MK, TATSUKA M, FUSE Y, KIYOSHI W, KAKUNAGA T: A tyrosine-specific protein kinase inhibitor, acyno-3ethoxy-4hydroxy-5-phenylthio-methylcinnamamide, blocks the phosphorylation of tyrosine kinase substrate in intact cells. Jpn. J. Cancer Res. (1990) 81:645–652.
   PubMedGoogle Scholar
• SHIRAISHI T, OWADA MK, TATSUKE M, YAMASHITA T, WATANABE K, KAKUNAGA T: Specific inhibitors of tyro-sine-specific protein kinases: properties of 4-hydroxy-cinnamamide derivatives in vitro. Cancer Res. (1989) 49:2374–2378.
   PubMed Web of Science ®Google Scholar
• WATANABE T, KUME T, TSUNEIZUMI K, KONDO K, SHI-RAISHI T, OISHI M: Synergistic induction of erythroid differentiation of mouse erythroleukemia cells by in-hibitors of topoisomerases and protein tyrosine ki-nases. Exp. Cell Res. (1992) 199:269–274.
   PubMed Web of Science ®Google Scholar
• ONODA T, IINUMA H., SASAKI Y, HAMADA M, ISSHIKI K, NAGANAWA H, TAKEUCHI T: Isolation of a novel tyro-sine kinase inhibitor, lavendustin A, fromStreptomyces griseolavendus. J. Nat. Prod. (1989) 52:1252–1257.
   PubMed Web of Science ®Google Scholar
• HSU CYJ, PERSONS P, SPADA AP, BEDNAR RA, LEVITSKI A, ZILBERSTEIN A: Kinetic analysis of the inhibition of the epidermal growth factor receptor tyrosine kinase by lavendustin-A and its analogues. J. Biol. Chem. (1991) 266:21105–21112.
   PubMed Web of Science ®Google Scholar
• ONODA T, ISSHIKI K, TAKEUCHI T, TATSUTA K, UMEZAWA K: Inhibition of tyrosine kinase and epider-mal growth factor receptor internalization by laven-dustin A methyl ester in cultured A431 cells. Drugs Exptl. din. Res. (1990) 16:249–253.
   PubMed Web of Science ®Google Scholar
• CHEN FIX, BOIZIAU J, PARKER F, MAROUN R, TOCQLTE B, ROQUES BP, GARBAYJAUREGLTIBERRY C: Synthesis and structure-activity studies of a series of Khydrox-yben-zyl)amittoisalicylates as inhibitors of EGF receptor-as-sociated tyrosine kinase activity. J. Med. Chem. (1993) 36:4094–4098.
   PubMed Web of Science ®Google Scholar
• SMYTH MS, STEFANOVA I, HARTMANN F, HORAK ID, OSHEROV N, LEVITZKI A, BURKE TR: Non-amine based analogues of lavendustin-A as protein-tyrosine kinase inhibitors. J. Med. Chem. (1993) 36:3010–3014.
   PubMed Web of Science ®Google Scholar
• SMY11-1 MS, STEFANOVA I, HORAK ID, BURKE TR: Hy-droxylated 2- (5'-s alicyOnaphthalenes as protein-tyro-sine kinase inhibitors. J. Med. Chem. (1993) 36:3015–3020.
   PubMedGoogle Scholar
• BURKE TR, LIM B, MARQUEZ VE, LI Z-H, BOLEN JB, STEFANOVA I, HORAK ID: Bicyclic compounds as ring-constrained inhibitors of protein-tyrosine kinase p561ck. J. Med. Chem. (1993) 36:425–432.
   PubMed Web of Science ®Google Scholar
• UEHARA Y, MURAKAMI Y, SUGIMOTO Y, MIZUNO S: Mechanism of reversion of Rous sarcoma virus trans-formation by herbitnycin reduction of total phospho-tyrosine levels due to reduced kinase activity and Increased turnover of p60v-srcl. Cancer Res. (1989) 49:780–785.
   PubMed Web of Science ®Google Scholar
• MURAKAMI Y, MIZUNO S, HORI M, UEHARA Y: Reversal of transformed phenotypes by herbinitycin A in src oncogene expressed rat fibroblasts. Cancer Res. (1988) 48:1587–1590.
   PubMed Web of Science ®Google Scholar
• SUZUKAKE-TSUCHIYA K, MORIYA Y, HORI M, UEHARA Y, TAKEUCHI T: Induction by herbimycin A of contact Inhibition in v-src- expressed cells. J. Antibiot. (1989) 42:1831–1837.
   PubMed Web of Science ®Google Scholar
• FUKAZAWA H, MIZUNO S, UEHARA Y: Effects of herbimy-cin A and various SH-reagents on p60v-src. Biochem. Biopbys. Res. Comm. (1990) 173:276–282.
   PubMed Web of Science ®Google Scholar
• UEHARA Y, FUKAZAWA H, MURAKAMI Y, MIZUNO 5: Irreversible inhibition of v-src tyrosine kinase activity by herbimycin A and its abrogation by sulfhydryl com-pounds. Biochem. Biophys. Res. Commun. (1989) 163:803–809.
   PubMed Web of Science ®Google Scholar
• GARCIA R, PARIKH NU, SAYA H, GALLICK GE: Effect of herbimycin-A on growth and pp60c-src activity in hu-man colon tumor cell lines. Oncogene (1991) 6: 1983-1989.
   Google Scholar
• FUKAZAWA H, LI PM, YAMAMOTO C, MURAKAMI Y, MIZUNO S, UEHARA Y: Specific inhibition of cytoplas-mic protein tyrosine kinases by herbimycin-A in vitro. Biochem. Pharmacol. (1991) 42:1661–1671.
   PubMed Web of Science ®Google Scholar
• MANDANAS RA, LEIBOWITZ DS, GHAREHBAGHI K, TAUCHI T, BURGESS GS, MIYAZAWA K, JAYARAM HN, BOSWELL HS: Role of p21 RAS in p210 bcr-abl transfor-mation of murine myeloid cells. Blood (1993) 82: 1838-1847.
   Google Scholar
• OKABE M, UEHARA Y, MIYAGISHIMA T, ITAYA T, TANAKA M, ICUNIEDA Y, KUROSAWA M, MIYAZAKI T: Effect of herbimycin-A, an antagonist of tyrosine kinase, on bcr/abl oncoprotein-associated cell proliferations - ab-rogative effect on the transformation of murine he-matopoietic cells by transfection of a retroviral vector expressing oncoprotein p210(bcriabf) and preferential inhibition on Ph(1)-positive leukemia cell growth. Blood (1992) 80:1330–1338.
   PubMed Web of Science ®Google Scholar
• HONMA Y, OICABE-ICADO J, KASUKABE T, HOZUMI M, KODAMA H, KAJIGAYA S, SLTDA T, MIURA: Herbimycin A, an inhibitor of tyrosine ktn2se, prolongs survival of mice inoculated with myeloid leukemia Cl cells with high expression of v-abi tyrosine kinase. Cancer Res, (1992) 52:4017–4020.
   Google Scholar
• Demonstration of in vivo antitumour activity.
   Google Scholar
• HONMA Y, KASUKABE T, HOZUMI M, SHIBATA K, OMURA S: Effects of herbhnycin-A derivatives on growth and differentiation of K562 human leukemic cells. Anti-cancer Res. (1992) 12:189–192.
   PubMed Web of Science ®Google Scholar
• HONMA Y, KASUKABE T, HOZUMI M, MASEKI N, SAKURAI M, SAKASHITA A, TSURUOKA N: Induction of differentia-tion of human leukemia cells with a structurally altered c-abl (bcr/abl) gene by herbimycin A, an inhibitor of tyrosine kinase activity. Leukemia (1992) 6:229–231.
   PubMed Web of Science ®Google Scholar
• HONMA Y, OKABE-ICADO J, HOZUMI M, UEHARA Y, MIZUNO S: Induction of erythroid differentiation of K562 human leukemic cells by herbimycin A, an inhibi-tor of tyrosine kinase activity. Cancer Res. (1989) 49:331–334.
   PubMed Web of Science ®Google Scholar
• KONDO K, WATANABE T, SASAKI H, UEHARA Y, OISHI M: Induction of in vitro differentiation of mouse em-bryonal carcinoma (F9) and erythroleukemia (MEL) cells by herbimycin A, an inhibitor of protein phospho-rylation. J. Cell Biol. (1989) 109:285–293.
   PubMed Web of Science ®Google Scholar
• KATAGIRI K, KATAGIRI T, ICAJIYAMA K, UEHARA Y, YAMAMOTO T, YOSHIDA T: Modulation of monocytic differentiation of HL-60 cells by inhibitors of protein tyrosine kinases Cellular Immunol. (1992) 140:282–294.
   Google Scholar
• HAMAGUCHI M, XIAO H, UEHARA Y, OHNISHI Y, NAGAI Y: Herbimycin-A inhibits the association of p60(v-src) with the cytoskeletal structure and with phosphatidyli-nosito1-3' kinase. Oncogene (1993) 8:559–564.
   PubMed Web of Science ®Google Scholar
• MATSUYOSHI N, HAMAGUCHI M, TANIGUCHI S, NA-GAFUCHI A, TSUKITA S, TAKEICHI M: Cadherin-mediated cell-cell adhesion is perturbed by v-src tyrosine phos-phorylation in metastatic fibroblasts. J. Cell Biol. (1992) 118:703–714.
   PubMed Web of Science ®Google Scholar
• TANIGUCHI M, UEHARA Y, MATSUYAMA M, TAICAHASHI M: Inhibition of ret tyrosine kinase activity by herbitny-cin-A. Biochem. Blophys. Res. Comm. (1993) 195:208–214.
   PubMed Web of Science ®Google Scholar
• WHITESELL L, SHIFRIN SD, SCHWAB G, NECKERS LM: Benzoquinonoid ansamycins possess selective tuumori-cidal activity unrelated to src kinase inhibition. Cancer Res. (1992) 52:1721–1728.
   PubMed Web of Science ®Google Scholar
• SANTINI F, BEAVEN MA: Nonselective actions of her-bitnycin A. Immunol. Today (1993) 14:369–370.
   PubMedGoogle Scholar
• THOMPSON AM, REWCASTLE GW, TERCEL M, DOBRUSIN EM, FRY DW, KRAKER AJ, DENNY WA: Tyrosine kinase inhibitors. 1. Structure- activity relationships for inhi-bition of epidermal growth factor receptor tyrosine kinase activity by 2,3-dihyro-2thioxo-1H- indole-3-al-kanoicacids and 2,2'-dithiobis(H-indole-3-alkanoic ac-ids). J. Med. Chem. (1993) 36:2459–2469.
   Google Scholar
• THOMPSON AM,, FRY DW, KRAKER AJ, DENNY WA: Tyro-sine kinase inhibitors. 2. Synthesis of 2,2'-dithiobis(1H-indole-3-alkanok acids and 2,2'-dithiobis (1H-indole-3-alkanoic acids). J Med. Chem. (1994) 37:598–609.
   Google Scholar
• FRY DW, KRAKER AJ, CONNORS RC, ELLIOTT WL, NELSON JM, SHOWALTER HDH, LEOPOLD WR: Strategies for the discovery of novel tyrosine kinns.. inhibitors with an-ticancer activity. Anticancer Drug Design. (1994) In press.
   Google Scholar
• KRAKER AJ, JONES JA, SCHEMMEL ME, MOORE CW: Inhi-bition of epidermal growth factor receptor tyrosine kinase by 2- thioindoles, a new structural class of tyrosine kinase inhibitor. Proc. Am. Assoc. Cancer Res. (1993) 34:408.
   Google Scholar
• LEOPOLD WR, PRZYBRANOWSKI SA, HOOK ICE, AM-BROSO L, FRY DW: Modulation of the growth inhibitory properties of a novel class of protein tyrosine kinase Inhibitors, the 2-thioindoles, by physiological concen-trations of glutathione. Proc. Am. Assoc. CancerRes. (1993) 34:408.
   Google Scholar
• NELSON JM, AMBROSO LA, FRY DW: Specific inhibition of bFGF- mediated tyrosine phosphorylation in fi-broblasts treated with 2- thioindoes, a new structural class of tyrosine kinase inhibitors. Proc. Am. Assoc. Cancer Res. (1993) 34:408.
   Google Scholar
• BARKER AJ, DAVIES DH, BROWN DS, WOODBURN JR, GREEN LR, CARLIDGE SA, WAKELING. Structure activity relationships of 4-ani11noquinazolines as inhibitors of EGFR-tyrosine kinase activity. Ann. Oncol. (1994) 5:120.
   Google Scholar
• GEISSLER JF, TRAXLER P, REGENASS U, MURRAY BJ, ROE-SEL JL, MEYER T, MCGLYNN E, STORNI A, LYDON NB: Thiazolidine-diones. Biochemical and biological activ-ity of a novel class of tyrosine protine kinase inhibitors. J Biol. Chem. (1990) 265:22255–22261.
   Google Scholar
• TRAXLER PM, WACKER O, BACH HL, GEISSLER JF, KUMP W, MEYER T, REGENASS U, ROESEL JL, LYDON N: Sulfonyl-benzoyl-nitrostyrenes: Potential bisubstrate type in-hibitors of the EGF-receptor tyrosine protein kinase. J. Med. Chem. (1991) 34:2328–2337.
   PubMed Web of Science ®Google Scholar
• TRAXLER P, BUCHDUNGER E, METT H, MEYER T, RE-GENASS U, ROESEL J, TRINKS U, LYDON N: Aminoalkyl-acrylophenones - selective inhibitors of EGF-R protein tyrosine kinase. Proc. Am. Assoc. Cancer Res. (1992) 33:527.
   Google Scholar
• GEISSLER JF, ROESEL JL, MEYER T, TRINKS UP, TRAXLER P, LYDON NB: Benzopyranones and benzothiopyra-nones: A class of tyrosine protein kinase inhibitors with selectivity for the v-abl kinase. Cancer Res. (1992) 52:4492–4498.
   PubMed Web of Science ®Google Scholar
• BUCHDUNGER E, TRINKS U, METT H, REGENASS U, MULLER M, MEYER T, MCGLYNN E, PINNA LA, TRAXLER P,LYDON NB: 4,5-Dianilinophthalimkie• A protein tyro-sine kinase inhibitor with selectivity for the epidermal growth factor receptor signal transduction pathway and potent in vivo antitumor activity. Proc. Natl. Acad. Sci. USA (1994) 91:2334–2338.
   PubMed Web of Science ®Google Scholar
• Demonstrates and specific inhibition of EGF or erbB-2 receptors can produce antitumour effects in vivo.
   Google Scholar
• BALLINARI D, CAPOLONGO L, BUZZETTI F, GRECO F, AMBOLDI N, MELEGARO G, BRASCA MG, GRANDI M, PENCO. S, TRIZIO D: 3-Arylidene-2-oxindoles: A new class of tyrosine kinase inhibitors: A structure/activity study. Proc. Am Assoc. Cancer Res. (1993) 34:387.
   Google Scholar
• GRAZIANI A, GRAMAGLIA D, DALLA ZONCA P, COMO-GLIO PM: Hepatocyte growth factor/scatter factor stimulates the ras -guanine nucleotide exchanger. J. Biol. Chem. (1993) 268:9165–9168.
   PubMed Web of Science ®Google Scholar